Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology

References

• Kamili QU, Menter A. Topical treatment of psoriasis. Curr Probl Dermatol. 2009;38:37–58.
   PubMedGoogle Scholar
• Bailey J, Whitehair B. Topical treatments for chronic plaque psoriasis. Am Fam Phys. 2010;81(5):596.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Linkner RV, Suarez FM, et al. An investigator-initiated, double-blind, vehicle-controlled pilot study: assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis. J Am Acad Dermatol. 2014;71(5):954–959.
   PubMed Web of Science ®Google Scholar
• Bernhard J, Whitmore C, Guzzo C, et al. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies. J Am Acad Dermatol. 1991;25(6 Pt 2):1170–1174.
   PubMed Web of Science ®Google Scholar
• Katz HI, Gross E, Buxman M, et al. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis. J Am Acad Dermatol. 1991;25(6 Pt 2):1175–1178.
   PubMed Web of Science ®Google Scholar
• Blum G, Yawalkar S. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991;25(6 Pt 2):1153–1156.
   PubMed Web of Science ®Google Scholar
• Goldberg B, Hartdegen R, Presbury D, et al. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991;25(6 Pt 2):1145–1148.
   PubMed Web of Science ®Google Scholar
• Mensing H, Korsukewitz G, Yawalkar S. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. J Am Acad Dermatol. 1991;25(6 Pt 2):1149–1152.
   PubMed Web of Science ®Google Scholar
• Pariser D, Bukhalo M, Guenthner S, et al. Two multicenter, randomized, double-blind, parallel group comparison studies of a novel enhanced lotion formulation of halobetasol propionate, 0.05% versus its vehicle in adult subjects with plaque psoriasis. J Drugs Dermatol. 2017;16(3):234–240.
   PubMed Web of Science ®Google Scholar
• Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol. 1991;25(6 Pt 2):1166–1169.
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48(5):760–767.
   PubMed Web of Science ®Google Scholar
• Kaidbey K, Kopper SC, Sefton J, et al. A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermatol. 2001;40(7):468–471.
   PubMed Web of Science ®Google Scholar
• Gold LS, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a Halobetasol/Tazarotene fixed combination in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase III randomized controlled trials. J Am Acad Dermatol. 2018;79(2):287–293.
   PubMed Web of Science ®Google Scholar
• Sugarman JL, Weiss J, Tanghetti EA, et al. Safety and efficacy of a fixed combination Halobetasol and Tazarotene lotion in the treatment of moderate-to-severe plaque psoriasis: a pooled analysis of two phase 3 studies. J Drugs Dermatol. 2018;17(8):855–861.
   PubMed Web of Science ®Google Scholar
• Sugarman JL, Gold LS, Lebwohl MG, et al. A Phase 2, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a Halobetasol/Tazarotene fixed combination in the treatment of plaque psoriasis. J Drugs Dermatol. 2017;16(3):194–201.
   Web of Science ®Google Scholar
• Stein Gold L, Kircik LH, Pariser D, et al. Rapid onset of action in patients with moderate-to-severe plaque psoriasis with Halobetasol 0.01%/Tazarotene 0.045% fixed combination. J Drugs Dermatol. 2018;17(8):863–868.
   PubMed Web of Science ®Google Scholar
• Pariser DM, Green LJ, Stein Gold L, et al. Halobetasol 0.01%/Tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: maintenance of therapeutic effect after cessation of therapy. J Drugs Dermatol. 2018;17(7):723–726.
   PubMed Web of Science ®Google Scholar
• Kircik LH, Papp KA, Stein Gold L, et al. Assessing the synergistic effect of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2019;18(3):279–284.
   PubMed Web of Science ®Google Scholar
• Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(3):61–67.
   PubMedGoogle Scholar
• Tan X, Feldman SR, Chang J, et al. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv. 2012;9(10):1263–1271.
   PubMed Web of Science ®Google Scholar
• Bhatia ND, Pariser DM, Kircik L, et al. Safety and efficacy of a halobetasol 0.01%/tazarotene 0.045% fixed combination lotion in the treatment of moderate-to-severe plaque psoriasis: a comparison with halobetasol propionate 0.05% cream. J Clin Aesthet Dermatol. 2018;11(11):15–19.
   PubMedGoogle Scholar
• Ye L, Lv C, Man G, et al. Abnormal epidermal barrier recovery in uninvolved skin supports the notion of an epidermal pathogenesis of psoriasis. J Invest Dermatol. 2014;134(11):2843–2846.
   PubMed Web of Science ®Google Scholar
• Wolf R, Orion E, Ruocco E, et al. Abnormal epidermal barrier in the pathogenesis of psoriasis. Clin Dermatol. 2012;30(3):323–328.
   PubMed Web of Science ®Google Scholar
• Bergboer JG, Zeeuwen PL, Schalkwijk J. Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. J Invest Dermatol. 2012;132(10):2320–2321.
   PubMed Web of Science ®Google Scholar
• Tamburic S, Craig DQ. Rheological evaluation of polyacrylic acid hydrogels. Pharm Pharmacol Commun. 1995;1:107–109.
   Google Scholar
• Scherer GW. Theory of drying. J Am Ceramic Soc. 1990;73(1):3–14.
   Web of Science ®Google Scholar
• Cohen SN, Baron SE, Archer CB. Guidance on the diagnosis and clinical management of psoriasis. Clin Exp Dermatol. 2012;37(Suppl 1):13–18.
   PubMed Web of Science ®Google Scholar
• Dawn A, Yosipovitch G. Treating itch in psoriasis. Dermatol Nurs. 2006;18(3):227–233.
   PubMedGoogle Scholar
• Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. 2008;26(4):380–386.
   PubMed Web of Science ®Google Scholar
• Raut AS, Prabhu RH, Patravale VB. Psoriasis clinical implications and treatment: a review. Crit Rev Ther Drug Carrier Syst. 2013;30(3):183–216.
   PubMed Web of Science ®Google Scholar
• Tidman MJ. Improving outcomes in patients with psoriasis. Practitioner. 2013;257(27–30):3.
   Google Scholar
• Caussin J, Groenink HWW, Graaff A. M D, et al. Lipophilic and hydrophilic moisturizers show different actions on human skin as revealed by cryoscanning electron microscopy. Exp Dermatol. 2007;16(11):891–898.
   PubMed Web of Science ®Google Scholar
• Thorneloe RJ, Bundy C, Griffiths CE, et al. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20–31.
   PubMed Web of Science ®Google Scholar
• Zschocke I, Mrowietz U, Karakasili E, et al. Non‐adherence and measures to improve adherence in the topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 2014;28(Suppl 2):4–9.
   PubMed Web of Science ®Google Scholar
• Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408–414.
   PubMedGoogle Scholar
• Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol. 2006;20(4):370–379.
   PubMed Web of Science ®Google Scholar
• Hougier FG, Cook-Bolden FE, Rodriguez D, et al. Critical considerations of optimizing topical corticosteroid therapy. J Clin Aesthet Dermatol. 2015;8(Suppl 1):S2–S14.
   Google Scholar
• Ryan S. Psoriasis: characteristics, psychosocial effects and treatment options. Br J Nurs. 2008;17(5):284–290.
   PubMedGoogle Scholar
• Eastman WJ, Malahias S, Delconte J, et al. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis. 2014;94(1):46–53.
   PubMed Web of Science ®Google Scholar
• Housman TS, Mellen BG, Rapp SR, et al. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70(6):327–332.
   PubMed Web of Science ®Google Scholar